About Theraclion

Company Description

At Theraclion we believe that surgery, as we know it, is outdated. It converts optimistic patients into anxious individuals, brilliant doctors into exhausted system executors and stretches healthcare systems to the limit. We have disrupted this convention by creating extracorporeal treatment platforms.

We replace surgery with a robotic treatment from outside the body using High Intensity Focussed Ultrasound (HIFU). Our leading edge echotherapy platforms are currently CE marked in non-invasive treatment of varicose veins with SONOVEIN® and of breast fibroadenomas and thyroid nodules with Echopulse®. Located in Malakoff, near Paris, our employees live and breath innovation by extensive clinical research and harness artificial intelligence to reshape surgery by making non-invasive echotherapy the new standard. Located in Malakoff, near Paris, Theraclion brings together a team of 25 people, more than half of whom are dedicated to R&D and clinical trials.

Year founded

2004

Served area

Worldwide

Headquarters

102 Rue Etienne Dolet, 92240 Malakoff – France

Shareholder information

Shares outstanding

28,828,412

IPO

April 25, 2014

Stock exchange(s)

Euronext Paris

Contact

Newsletter

Subscribe to our newsletter and receive information about recent IPOs, news in the European capital market and more.